Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8026 to 8040 of 9040 results

  1. Ultra-radical (extensive) surgery for advanced ovarian cancer (IPG470)

    This guidance has been updated and replaced by NICE HealthTech guidance 668.

    Withdrawn guidance

  2. Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease [TSID9147]

    In development Reference number: GID-TA11327 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line in people 5 years and over [ID6691]

    In development Reference number: GID-TA11909 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Fertility problems: assessment and treatment (CG156)

    This guideline has been updated and replaced by NICE guideline NG257.

    Withdrawn guideline

  7. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Discontinued Reference number: GID-TA10961

    Technology appraisal guidance
    Discontinued

  8. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development Reference number: GID-TA11070 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development Reference number: GID-TA11272 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued Reference number: GID-TA11255

    Technology appraisal guidance
    Discontinued

  11. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]

    In development Reference number: GID-TA11634 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    Discontinued Reference number: GID-TA11476

    Technology appraisal guidance
    Discontinued

  14. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

    Technology appraisal guidance
    Discontinued

  15. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    Discontinued Reference number: GID-TA10995

    Technology appraisal guidance
    Discontinued